Thabane M - Search Results

1

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast Cancer.

Stellato D, Thabane M, Eichten C, Delea TE. Stellato D, et al. Among authors: thabane m. Curr Oncol. 2021 Jan 14;28(1):491-508. doi: 10.3390/curroncol28010051. Curr Oncol. 2021. PMID: 33466914 Free PMC article.

2

Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.

Stellato D, Thabane ME, Chandiwana D, Park J, Delea TE. Stellato D, et al. Among authors: thabane me. Pharmacoeconomics. 2021 Jul;39(7):853-867. doi: 10.1007/s40273-021-01028-3. Epub 2021 May 18. Pharmacoeconomics. 2021. PMID: 34002341

3

Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.

Stellato D, Thabane ME, Park J, Chandiwana D, Delea TE. Stellato D, et al. Among authors: thabane me. Pharmacoeconomics. 2021 Sep;39(9):1045-1058. doi: 10.1007/s40273-021-01027-4. Epub 2021 Jun 9. Pharmacoeconomics. 2021. PMID: 34105083

4

Preferences of Canadian patients and physicians for adjuvant treatments for melanoma.

Stellato D, Thabane M, Eichten C, Delea TE. Stellato D, et al. Among authors: thabane m. Curr Oncol. 2019 Dec;26(6):e755-e765. doi: 10.3747/co.26.5085. Epub 2019 Dec 1. Curr Oncol. 2019. PMID: 31896946 Free PMC article.

5

Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.

Delea TE, Amdahl J, Wang A, Amonkar MM, Thabane M. Delea TE, et al. Among authors: thabane m. Pharmacoeconomics. 2015 Apr;33(4):367-80. doi: 10.1007/s40273-014-0241-z. Pharmacoeconomics. 2015. PMID: 25488880

6

Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada.

Chua A, Perrin A, Ricci JF, Neary MP, Thabane M. Chua A, et al. Among authors: thabane m. Curr Oncol. 2018 Feb;25(1):32-40. doi: 10.3747/co.25.3532. Epub 2018 Feb 28. Curr Oncol. 2018. PMID: 29507481 Free PMC article.

7

Burden of illness for metastatic melanoma in Canada, 2011-2013.

Ernst DS, Petrella T, Joshua AM, Hamou A, Thabane M, Vantyghem S, Gwadry-Sridhar F. Ernst DS, et al. Among authors: thabane m. Curr Oncol. 2016 Dec;23(6):e563-e570. doi: 10.3747/co.23.3161. Epub 2016 Dec 21. Curr Oncol. 2016. PMID: 28050145 Free PMC article.

8

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G. Forsythe A, et al. Among authors: thabane m. Breast Cancer (Dove Med Press). 2018 May 4;10:69-78. doi: 10.2147/BCTT.S162841. eCollection 2018. Breast Cancer (Dove Med Press). 2018. PMID: 29765247 Free PMC article.

9

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G. Forsythe A, et al. Among authors: thabane m. Cancer Manag Res. 2018 May 4;10:1015-1025. doi: 10.2147/CMAR.S162714. eCollection 2018. Cancer Manag Res. 2018. PMID: 29765249 Free PMC article.

10

Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada.

Chua A, Perrin A, Ricci JF, Neary MP, Thabane M. Chua A, et al. Among authors: thabane m. Curr Oncol. 2018 Aug;25(4):e354-e355. doi: 10.3747/co.25.4233. Epub 2018 Aug 14. Curr Oncol. 2018. PMID: 30111982 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page